CAR38-MILs

N/A

Report date: 2025/03/14 16:54:59

Base Information

Drug NameCAR38-MILs
Drug Alias Nameanti-CD38-4-1BB-CD3zeta CAR (WindMIL Therapeutics/Johns Hopkins University School of Medicine)anti-CD38 CAR-marrow infiltrating lymphocyte therapy (Johns Hopkins/WindMIL Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulators
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJohns Hopkins University School Of MedicineWindmil Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A